TheraVet Updates on Its Development and Portfolio Strategy

Regulatory News:

TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in companion animals, provides an update on its development strategy.

Enrico Bastianelli, Managing Director at TheraVet, states: “Since the IPO of TheraVet in June 2021, we have been committed to deploying therapeutic innovations to treat osteoarticular pathologies in companion animals. Important milestones in this development were reached in 2022 with the acquisition of the BIOCERA-VET SMARTGRAFT products, and the collection of numerous clinical cases in more than eight indications from an international network of veterinarians. In 2023, we intend to reinforce the positioning of our range of products in indications with high added value, as highlighted by our recent collaboration in the treatment of bone cysts in horses. Following the recommendation of animal health experts, we will also direct our VISCO-VET study to the treatment of elbow osteoarthritis in dogs. Finally, we will continue to develop new products in order to better meet the needs of veterinarians. The combination of all these elements reinforces our strategy aimed at positioning TheraVet as a major player in the market for osteoarticular treatments in animal health.”

Pursue of the positioning in high added value indications

In 2022, TheraVet collected more than 60 positive clinical case reports in 8 – among the most important - indications from 25 European and American veterinarians. In 2023, TheraVet intends to strengthen its position in indications with high added value for which its product range provides unique solutions:

• In February 2023, building on its success in intraosseous applications, TheraVet announced its entry into the equine market through a collaboration with Dr Ter Braake. Here, the aim is to evaluate its ready-to-use bone cement as a new treatment option for bone cysts, a market of ~ 200,000 annual procedures in yearlings (racehorses in their second year).
• During the second quarter of 2023, Centers of Reference in osteosarcoma will be opened in Europe and the United States to allow owners to present their companion animals suffering from osteosarcoma to specialized veterinarians performing, among others, cementoplasty with the BIOCERA-VET OSTEOSARCOMA RTU. This initiative will be supported by promotional events, marketing activities and scientific publications.
• By mid-2023, studies in collaboration with international opinion leaders will be initiated with the aim of demonstrating the benefit of using BIOCERA-VET in innovative surgical approaches.

Strengthening product credibility among prescribers